Clinical Trial Update: Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003) [Phase 2]

View source ↗

Summary

Phase 2 trial update on MK0594 for overactive bladder showed safety and efficacy data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• MK0594

Snippet

Sponsor: Vyne Therapeutics Inc. | Conditions: Urinary Incontinence, Overactive Bladder | Phase 2 | Status: COMPLETED